VTv Therapeutics Files $250M Mixed Securities Shelf

Seeking AlphaApr 11 05:19

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozolomide, in newly dia

PR NewswireMar 19 20:30

VTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees

TipRanksMar 14 20:12

VTv Therapeutics Q4 EPS $(1.67) Up From $(2.28) YoY

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.67) per share. This is a 26.75 percent increase over losses of $(2.28) per share from the same period last year.

BenzingaMar 13 20:03

Press Release: VTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update -- Recently completed $51 million PIPE from healthcare-focused institutional inve

Dow JonesMar 13 20:00

VTv Therapeutics 4Q Loss/Shr $1.67 >VTVT

VTv Therapeutics 4Q Loss/Shr $1.67 >VTVT

Dow JonesMar 13 20:00